101P Significant Antitumor Activity in A Randomized Phase 2 Study Comparing 2 Schedules of Nktr-102 In Patients (Pts) with Metastatic Breast Cancer (Mbc)

Antitumor Activity ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Cited By ~ 3

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Acta Oncologica ◽

10.1080/0284186x.2020.1851045 ◽

2020 ◽

pp. 1-8

Author(s):

Anne Sofie Brems-Eskildsen ◽

Søren Linnet ◽

Hella Danø ◽

Adam Luczak ◽

Peter Michael Vestlev ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Oral Capecitabine ◽

Phase 2 Study ◽

Metronomic Treatment ◽

Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 study

10.1158/1538-7445.sabcs16-s2-05 ◽

2017 ◽

Cited By ~ 6

Author(s):

HS Han ◽

V Diéras ◽

ME Robson ◽

M Palácová ◽

PK Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study

10.1158/1538-7445.sabcs19-p5-14-05 ◽

2020 ◽

Author(s):

Elgene Lim ◽

Frances Boyle ◽

Meena Okera ◽

Sherene Loi ◽

Sema Sezgin Goksu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Previously Treated ◽

The Impact ◽

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial

Cancer ◽

10.1002/cncr.30141 ◽

2016 ◽

Vol 122 (19) ◽

pp. 2961-2970 ◽

Cited By ~ 5

Author(s):

Jan C. Drooger ◽

Harm van Tinteren ◽

Steffen M. de Groot ◽

Albert J. ten Tije ◽

Hiltje de Graaf ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Phase 2 Study ◽

Group Trial ◽

Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects withBRCA1orBRACA2mutation and metastatic breast cancer

10.1158/0008-5472.sabcs12-ot2-3-07 ◽

2012 ◽

Author(s):

SJ Isakoff ◽

S Pulhalla ◽

SP Shepherd ◽

N Falotico ◽

B Kaufman ◽

...

Keyword(s):

Breast Cancer ◽

Parp Inhibitor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Faculty Opinions recommendation of Abstract P6-11-12: Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735553267.793559058 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Subgroup Analysis ◽

Disease Burden ◽

Metastatic Breast ◽

Prior Treatment ◽

Phase 2 ◽

Phase 2 Study

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer

International Journal of Cancer ◽

10.1002/ijc.33613 ◽

2021 ◽

Author(s):

Hyehyun Jeong ◽

Jae Ho Jeong ◽

Jeong Eun Kim ◽

Jin‐Hee Ahn ◽

Kyung Hae Jung ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Protective Effects ◽

Phase 2 ◽

Hormone Receptor Positive ◽

A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer

Cancer ◽

10.1002/cncr.24900 ◽

2010 ◽

Vol 116 (6) ◽

pp. 1440-1445 ◽

Cited By ~ 3

Author(s):

Gabriel N. Hortobagyi ◽

William Heim ◽

Laura Hutchins ◽

Edgardo Rivera ◽

Bernard Mason ◽

...

Keyword(s):

Breast Cancer ◽

Fixed Combination ◽

Metastatic Breast ◽

Daily Regimen ◽

Phase 2 ◽

Phase 2 Study

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

First Line Treatment